Synonym: N9-(3-(Dimethylamino)propyl)-N3,N3,N6,N6-tetramethylacridine-3,6,9-triamine hydrochloride
CAS Number: 2187367-10-6
Empirical Formula (Hill Notation): C22H32N5 · xHCl
Molecular Weight: 366.52 (free base basis)
Linear Formula: C22H32N5 · xHCl
Product Type: Chemical
| assay |
≥98% (HPLC) |
| color |
yellow to orange |
| form |
powder |
| InChI |
1S/C22H31N5/c1-25(2)13-7-12-23-22-18-10-8-16(26(3)4)14-20(18)24-21-15-17(27(5)6)9-11-19(21)22/h8-11,14-15H,7,12-13H2,1-6H3,(H,23,24) |
| InChI key |
UIWOQSJSDYDIQJ-UHFFFAOYSA-N |
| Quality Level |
100  |
| SMILES string |
CN(C)CCCNC1=C2C(C=C(N(C)C)C=C2)=NC3=C1C=CC(N(C)C)=C3 |
| solubility |
DMSO: 25 mg/mL, clear |
| storage condition |
desiccated |
| storage temp. |
2-8°C |
| Biochem/physiol Actions: |
3,6-DMAD is also called as N9-(3-(dimethylamino)propyl)-N3,N3,N6,N6-tetramethylacridine-3,6,9-triamine. It prevents the development of multiple myeloma (MM) tumor xenografts. |
| Biochem/physiol Actions: |
3,6-DMAD is an acridine derivative that selectively suppresses ER stress- (300 nM Thapsigargin) induced HT1080 cellular XBP1 mRNA splicing (Eff. conc. 500 nM), but not eIF2a phosphorylation, by directly inhibiting IRE1? RNase (endoribonuclease) activity and disrupting IRE1α oligomerization. 3,6-DMAD is shown to exhibit anti-multiple myeloma efficacy in cultures in vitro (%survival/[3,6-DMAD]/cell line/24 h = 13%/4 M/RPMI 8226 and 8%/1 μM/MM1.R) and completely suppress the expansion of established RPMI 8226 tumor in mice in vivo when administered via intraperitoneal injection (10 mg/kg q.o.d.). |
| Biochem/physiol Actions: |
3,6-DMAD is an acridine derivative. |
| Packaging: |
5, 25 mg in glass bottle |
| RIDADR |
NONH for all modes of transport |
| WGK Germany |
WGK 3 |
| Flash Point(F) |
Not applicable |
| Flash Point(C) |
Not applicable |
| Purity |
≥98% (HPLC) |
| Storage Temp. |
2-8°C |
| UNSPSC |
12352200 |
